Network genomic medicine(NGM)utilizes next-generation sequencing(NGS)based molecular multiplex diagnostics to look for genomic aberrations with potential therapeutic relevance.NGM Lung Cancer project in Germany works to implement personalized lung cancer care effectively in clinical routine.The network has grown constantly and currently includes about 300 referring institutions in Germany and molecular multiplex diagnostic is now routinely covered by major German health insurance companies.Currently,more than 5000 lung cancer patients(about 10%of lung cancer patients in Germany)are genotyped every year.The high throughput molecular diagnostics approach allows routine testing of many patients and enables it to competitively participate in global practice changing trials and to initiate multicenter trials.NGM Lung Cancer established a personalized early proof of concept clinical trial platform including clinical trials for all targetable mutations.The initiative of the National Network Genomic Medicine(nNGM)Lung Cancer started in 2018.The idea of nNGM is to extend the NGM model nationwide and thus to create access to highly innovative molecular diagnostics and innovative therapy for patients with advanced lung cancer.Currently,NGS-based molecular diagnostics has already covered for 65%of the German patients with advanced lung cancer.nNGM represents a best practice example now for rapid implementation of innovative genomic cancer medicine in clinical routine in a complex and diversified health care system.This article introduces the overview of the NGM Lung Cancer project in Germany and the successful experience of the nNGM Lung Cancer initiative,aiming to provide reference for integrating personalized cancer therapy into clinical routine in China.
维普
万方数据